There is no universal best medication for weight loss
Adan, GLP-1 receptor agonist GLP1-S reduces appetite while increasing dopamine reward signaling, Neuroscience Applied, Volume 3, 2024, 103925, ISSN 2772-4085
Moreover, patients losing 20-30% of their body weight also contributes to blood pressure lowering effects as well and going back to the earlier graph with 2 out of 3 patients not even being in the obese BMI category, suggests a large number of patients were probably able to reduce dose or stop their blood pressure medicine entirely but since they only had the data for a couple weeks we have to wait for confirmation on that
Phase 2 data showed retatrutide producing substantial reductions in liver fat fraction, opening a potential pathway for the drug to address MASLD as a formal indication, an area where no approved pharmacotherapy currently exists
What might it cost if approval changes the market